Towards Healthcare
Next-Gen Proteomics Market Size, Drivers and Key Challenges

Next-Gen Proteomics Market Opportunities and Key Trends

The increasing demand for personalized medicine and drug discovery in proteomics is driving the market expansion. Whereas, North America was dominant in the market, due to growing chronic disease incidences and accelerating advancements in healthcare infrastructure, and a strong life sciences industry.

Content

  • Insight Code: 5761
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The global next-gen proteomics market is being driven by a convergence of factors a surge in chronic diseases like cancer, cardiovascular, and autoimmune disorders

Asia Pacific is expected to grow at the fastest CAGR through 2034, fueled by rising healthcare expenditures, expanding R&D infrastructure, and a growing burden of chronic diseases.

Mass spectrometry leads in adoption due to its high precision in protein analysis, while protein microarrays are expected to see the fastest growth due to their utility in biomarker discovery and disease diagnostics

AI enables rapid and accurate interpretation of complex proteomics datasets, identifying biomarkers, predicting drug responses, and integrating multi-omics data.

High capital expenditure for advanced instruments, complex data analysis requiring skilled personnel, and limited accessibility in low-resource settings pose significant challenges.

Pharmaceutical and biotechnology companies are the dominant end-users due to their extensive drug discovery programs and precision medicine initiatives

Next-gen proteomics enables the identification and validation of protein targets, mechanism-of-action studies, and biomarker discovery, significantly shortening drug development timelines.
Any Questions